Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01161628
Other study ID # NSH 893
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received July 12, 2010
Last updated January 27, 2016
Start date April 2011
Est. completion date February 2016

Study information

Verified date January 2016
Source Northside Hospital, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Rituximab is an attractive agent to bring to the upfront treatment of chronic graft-versus-host disease (cGVHD) due to its favorable toxicity profile, its proven efficacy in the treatment of steroid-refractory cGVHD, and its ability to serve as a steroid sparing agent in other autoimmune diseases. The investigators hope to demonstrate that Rituximab has significant activity in cGVHD when utilized early in the course of the process. In addition, the investigators hope to show that the early use of Rituximab may allow for the earlier discontinuation of immunosuppression while obviating the need for long courses of systemic corticosteroids, which should translate into reduced treatment-related morbidity and mortality associated with cGVHD.


Description:

Although allogeneic hematopoietic stem cell transplantation (HSCT) remains an important curative therapy for many patients with hematological malignancies, treatment-related morbidity and mortality continue to be a major challenge. Chronic GVHD remains a major complication following allogeneic HSCT, with more than half of patients being affected. Although cGVHD has been associated with decreased relapse risk due to the well documented graft-versus-malignancy effect, it is also associated with significant adverse consequences in terms of morbidity, mortality, quality-of-life, and treatment costs associated with HSCT.

Rituximab has been investigated in a small number of patients with refractory cGVHD using the standard regimen of 375 mg/m2/week for 4 weeks. Ratanatharathorn et al. documented a sustained response in four of eight patients with steroid-refractory cGVHD with diffuse or localized sclerodermatous manifestations. Similarly, Canninga-vanDijk et al. and Okamoto et al. observed cases with clinical, laboratory and histological improvement after Rituximab treatment. Cutler et al. reported the results of their phase I-II study with Rituximab in 21 patients with steroid-refractory cGVHD. Treatment was well tolerated, and toxicity limited to infectious events, without any hematological toxicities and only a significant reduction in circulating immunoglobulins documented after therapy. Objective responses were documented in 70% of patients (including 10% complete response) primarily for those with skin and musculoskeletal involvement, allowing tapering, and in some cases withdrawing, of previous immunosuppressant therapy. A correlation between clinical response and decrease in the titre of antibodies against Y chromosome-encoded minor HLA antigens was shown. The results of these preliminary studies highlight the potential therapeutic activity of Rituximab on some cGVHD manifestations and a particularly high efficacy for skin involvement, including scleroderma. Recently, Zaja et al. confirmed the activity of Rituximab in refractory cGVHD in a larger series of 38 patients. Treatment was generally well tolerated and nearly 60% and 50% of patients had a clinical improvement of their skin and mouth manifestations, respectively. The median time-to-response was nearly 2 months and in some cases responses were durable. Responses were also detectable in some patients with eye, liver, lung, gut and joint involvement, allowing reduction and/or suspension of previous baseline immunosuppressive therapy in a significant number of patients


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 25
Est. completion date February 2016
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- First episode of extensive chronic GvHD, without residual or concurrent acute GvHD.

- Age 18 - 75

- Any primary diagnosis requiring treatment by allogeneic HSCT

- Recipient of an allogeneic stem cell transplant (bone marrow, peripheral blood stem cell, or cord blood) from a related or unrelated donor, minimum 80 days ago

- Conditioning regimen: Myeloablative or non-myeloablative

- Patient gives written informed consent

Exclusion Criteria:

- Creatinine > 2.0 mg/dl

- Uncontrolled, active infection

- Recurrent or progressive malignancy

- Anticipated life expectancy of less than 1 year

- Pregnant or breast feeding

- Contraindications to administration of the study intervention or known inability of the patient to tolerate the study intervention

- Patients with perceived fixed, irreversible defects (pulmonary involvement, contractures, etc.) which would not be expected to improve with the study intervention

- Residual or concurrent acute GVHD

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Rituximab
Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.

Locations

Country Name City State
United States Northside Hospital Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Northside Hospital, Inc. Blood and Marrow Transplant Group of Georgia

Country where clinical trial is conducted

United States, 

References & Publications (8)

Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004 Oct 15;104(8):2603-6. Epub 2004 Jul 13. — View Citation

Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15;108(2):756-62. Epub 2006 Mar 21. — View Citation

Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33. Review. — View Citation

Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, Katoh N, Kishimoto S, Shimazaki C. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006 Jan;20(1):172-3. — View Citation

Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, Ferrara JL, Uberti JP. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11. — View Citation

Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, Silver SM, Ferrara JL, Uberti JP. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000 Aug 15;133(4):275-9. — View Citation

Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, Appelbaum FR, Carpenter PA, Sanders JE, Kiem HP, Nash RA, Petersdorf EW, Moravec C, Morton AJ, Anasetti C, Flowers ME, Martin PJ. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004 Dec 1;104(12):3501-6. Epub 2004 Aug 3. — View Citation

Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007 Aug;40(3):273-7. Epub 2007 Jun 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Complete Response of cGVHD to Treatment. 2 years Yes
Primary Rate of Overall Response of cGVHD to Treatment 2 years Yes
Primary Rate of Partial Response of cGVHD to Treatment 2 years Yes
Secondary Requirement for Systemic Corticosteroid Use 2 years No
Secondary Time to Immunosuppression Withdrawal 2 years No
Secondary Incidence of Overall Survival 2 years No
Secondary Duration of Systemic Corticosteroid Use 2 years No
Secondary Incidence of Disease-free Survival 2 years No
Secondary Incidence of Non-relapse Mortality 2 years No
See also
  Status Clinical Trial Phase
Completed NCT02991846 - A Prospective Observational Study for Evaluating CGVHD
Recruiting NCT02291770 - Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells Phase 3
Terminated NCT01226420 - Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease Phase 2
Active, not recruiting NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01862965 - Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus Phase 2
Completed NCT02411474 - Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD N/A
Completed NCT02040623 - Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) Phase 2
Active, not recruiting NCT01158105 - Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) Phase 2
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Active, not recruiting NCT01366092 - Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 2
Not yet recruiting NCT06458127 - Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease N/A
Recruiting NCT05690971 - Psychosocial Mobile App for Chronic Graft-Versus-Host Disease N/A
Recruiting NCT02918188 - Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD Phase 2
Recruiting NCT01765660 - Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease Phase 2
Completed NCT01956903 - Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. Phase 1/Phase 2
Terminated NCT03584516 - GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Phase 2/Phase 3
Recruiting NCT04692376 - MSC for Treatment of cGVHD After Allo-HSCT Phase 2
Completed NCT02966301 - Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Phase 2
Terminated NCT01898377 - Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children Phase 2
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease